David Eidelberg

David Eidelberg
Nationality American
Education Columbia University, Harvard Medical School
Occupation Physician, Scientist
Employer The Feinstein Institute for Medical Research
Known for Medical Research
Website

David Eidelberg, MD, is a neuroscientist best known for applying functional imaging of the brain (MRI, PET scans) to diagnose neurological disease and chart its course. Eidelberg's studies were the first to identify specific changes in the patterns of brain-wide metabolic activity that could be linked to specific stages in the onset and development of Parkinson's disease and other movement disorders, such as dystonia, Tourette syndrome, and Huntington's disease.[1][2] The work has led to the development of novel image-based methods for assessing disease progression and responses to treatment, as well as for enhancing the accuracy of clinical diagnosis.

Early Life and Education

David Eidelberg earned his BA at Columbia University in 1977, and his MD from Harvard Medical School (HMS) in 1981.[3] After completing residency training in neurology at the Harvard-Longwood Area Training Program, he pursued postdoctoral training as a Moseley Traveling Fellow at the National Hospital, Queen Square, in London, and at Sloan-Kettering Institute in New York.

Academic Appointments

In 1988, David Eidelberg joined North Shore University Hospital in Manhasset, New York, where he established the Functional Brain Imaging Laboratory and the Movement Disorders Center. He is currently Director of the Feinstein Center for Neurosciences and Susan & Leonard Feinstein Professor of Neuroscience at The Feinstein Institute for Medical Research. He is also Director of the NIH Morris K. Udall Center of Excellence for Parkinson’s Disease Research, both at The Feinstein Institute for Medical Research in Manhasset, NY.[3] He is also an attending neurologist at North Shore University Hospital in Manhasset.

Principal Scientific Contributions

Eidelberg is internationally recognized for his pioneering work using functional imaging methods to characterize large-scale network abnormalities in brain disease. The characterization of distinct disease-specific metabolic networks relating to these disorders and the prospective quantification of pattern expression in individual cases have proved to be valuable for differential diagnosis and the objective assessment of disease progression and the effects of therapy. In particular, Eidelberg and his colleagues have used this approach to measure rates of network progression in preclinical carriers of the Huntington disease mutation, and in individuals with prodromal Parkinson's disease.[4] Additionally, his team was the first to demonstrate a consistent relationship between treatment-mediated network modulation in individual patients (measured using functional brain imaging) and independent descriptors of therapeutic outcome (measured using standardized clinical ratings).[5] This work set the stage for the recent introduction of functional brain networks as imaging biomarkers with which to assess novel therapies, such as gene therapy interventions for Parkinson’s disease. Eidelberg's network method has also proved useful in clarifying mechanisms of clinical penetrance in dominantly inherited neurological disorders such as primary torsion dystonia and Huntington’s disease.

Awards and Honors

Selected Publications (2006–2014)

References

  1. ↑ "Increased sensorimotor network activity in DYT1 dystonia: A functional imaging study". Brain 133 ((Pt 3)): 690–700. 2010. doi:10.1093/brain/awq017. PMC 2842516. PMID 20207699. Retrieved 5 February 2014.
  2. ↑ "Abnormal metabolic brain networks in Tourette syndrome". Neurology 76 (11): 944–952. 2011. doi:10.1212/WNL.0b013e3182104106. PMC 3271575. PMID 21307354. Retrieved 5 February 2014.
  3. 1 2 "Centers of Excellence". The Feinstein Institute for Medical Research. Retrieved 5 February 2014.
  4. ↑ "Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects". NeuroImage 54 (2): 1244–53. 2011. doi:10.1016/j.neuroimage.2010.09.028. PMC 2997135. PMID 20851193. Retrieved 5 February 2014.
  5. ↑ "Network modulation in the treatment of Parkinson’s disease". Brain 129 (Pt 10): 2667–78. 2006. doi:10.1093/brain/awl162.
  6. ↑ "Past Award Winners". American Academy of Neurology. Retrieved 5 February 2014.
  7. ↑ "Scientific and Special Advisors". Michael J. Fox Foundation. Retrieved 5 February 2014.
  8. ↑ "Scientific Advisory Board". Bachmann-Strauss Dystonia and Parkinson Foundation. Retrieved 5 February 2014.
  9. ↑ "Striking at the Causes of Parkinson's" (PDF). The Thomas Hartman Foundation for Parkinson's Research, Inc. Retrieved 5 February 2014.
  10. ↑ "Editorial Board". Journal of Nuclear Medicine. Retrieved 5 February 2014.
  11. ↑ "Editorial Board". Current Opinion in Neurology. Retrieved 5 February 2014.
  12. ↑ "Editorial Board". Annals of Neurology. Retrieved 5 February 2014.
  13. ↑ "About The Journal of Neuroscience". The Journal of Neuroscience. Retrieved 5 February 2014.
This article is issued from Wikipedia - version of the Sunday, February 28, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.